A JAK Inhibitor for the Treatment of Moderate to Severe Crohn's Disease
Crohn's Disease is a chronic, progressive, inflammatory bowel disease that damages the bowel over time and may result in decreased quality of life, hospitalizations, surgeries, and disability. The American Gastroenterological Association treatment guidelines for moderate to severe Crohn's Disease have been updated and new long-term goals for the management of the disease have been established.
There is a need for new treatment options, with a focus on long-term patient outcomes. A JAK inhibitor was recently approved for the treatment of moderate to severe Crohn's Disease. The objective of this webinar is to review Crohn's Disease, treatment guidelines, and the pivotal trials program for this recently approved JAK inhibitor.
- Discuss the epidemiology of Crohn's Disease and clinical burden of the disease that often requires multiple treatment options for patients.
- Review the Treat to Target approach from the STRIDE-II guidelines discussing the impact of disease progression and long-term outcomes with the early use of advanced treatment options for Crohn's Disease.
- Review and discuss the efficacy and safety data of a JAK inhibitor in patients with moderate to severe Crohn's Disease from its phase 3 pivotal trials program.
Russell D. Cohen, MD
Professor of Medicine, Pritzker School of Medicine
Director, Inflammatory Bowel Disease Center
Co-Director, Advanced IBD Fellowship Program
This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.
AbbVie US Medical Affairs
Registration is free for Members and Non-Members
For individuals from the media/press interested in attending, please email email@example.com.